Astellas receives european commission approval for first-in-class evrenzo™ (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease

Roxadustat is the first orally administered hypoxia-inducible factor (hif) prolyl hydroxylase (ph) inhibitor available for adult patients with anemia associated with chronic kidney disease in europe roxadustat is the first orally administered hypoxia-inducible factor (hif) prolyl hydroxylase (ph) inhibitor available for adult patients with anemia associated with chronic kidney disease in europe
FGEN Ratings Summary
FGEN Quant Ranking